Literature DB >> 31383636

Ponatinib treatment promotes arterial thrombosis and hyperactive platelets.

Alona Merkulova1, Steven C Mitchell1, Evi X Stavrou1,2, Gabriel L Forbes1, Alvin H Schmaier1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31383636      PMCID： PMC6693004          DOI： 10.1182/bloodadvances.2019000034

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  18 in total

1.  The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.

Authors:  Cassandra P Loren; Joseph E Aslan; Rachel A Rigg; Marie S Nowak; Laura D Healy; András Gruber; Brian J Druker; Owen J T McCarty
Journal:  Thromb Res       Date:  2014-11-18       Impact factor: 3.944

2.  Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Authors:  Chao Fang; Evi Stavrou; Alec A Schmaier; Nadja Grobe; Mariana Morris; Andrew Chen; Marvin T Nieman; Gregory N Adams; Gretchen LaRusch; Yihua Zhou; Matthew L Bilodeau; Fakhri Mahdi; Mark Warnock; Alvin H Schmaier
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

3.  Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

Authors:  Stéphane Prost; Francis Relouzat; Marc Spentchian; Yasmine Ouzegdouh; Joseph Saliba; Gérald Massonnet; Jean-Paul Beressi; Els Verhoeyen; Victoria Raggueneau; Benjamin Maneglier; Sylvie Castaigne; Christine Chomienne; Stany Chrétien; Philippe Rousselot; Philippe Leboulch
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

4.  The peroxisome proliferator-activated receptor γ agonist pioglitazone prevents NF-κB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway.

Authors:  Jiong Zhang; Ying Zhang; Fang Xiao; Yanyan Liu; Jin Wang; Hongyu Gao; Song Rong; Ying Yao; Junhua Li; Gang Xu
Journal:  Biochem Pharmacol       Date:  2015-12-07       Impact factor: 5.858

5.  The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.

Authors:  Marvin T Nieman; Mark Warnock; Ahmed A K Hasan; Fakhri Mahdi; Benedict R Lucchesi; Nancy J Brown; Laine J Murphey; Alvin H Schmaier
Journal:  J Pharmacol Exp Ther       Date:  2004-06-21       Impact factor: 4.030

6.  Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival.

Authors:  Elizabeth M Chislock; Colleen Ring; Ann Marie Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-09       Impact factor: 11.205

7.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

Review 8.  Nox and Inflammation in the Vascular Adventitia.

Authors:  Daniel N Meijles; Patrick J Pagano
Journal:  Hypertension       Date:  2015-11-09       Impact factor: 10.190

Review 9.  Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

Authors:  Javid J Moslehi; Michael Deininger
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

10.  Effects of food on the pharmacokinetics of ponatinib in healthy subjects.

Authors:  N I Narasimhan; D J Dorer; K Niland; F Haluska; Daryl Sonnichsen
Journal:  J Clin Pharm Ther       Date:  2013-07-25       Impact factor: 2.512
View more
  6 in total

Review 1.  Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.

Authors:  Melinda D Wu; Javid J Moslehi; Jonathan R Lindner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-04       Impact factor: 8.311

2.  Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors.

Authors:  Alona Telerman; Galit Granot; Chiya Leibovitch; Osnat Yarchovsky-Dolberg; Adi Shacham-Abulafia; Shirly Partouche; Moshe Yeshurun; Martin H Ellis; Pia Raanani; Ofir Wolach
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

Review 3.  Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data.

Authors:  Jennifer M Kwan; Evangelos K Oikonomou; Mariana L Henry; Albert J Sinusas
Journal:  Front Cardiovasc Med       Date:  2022-03-15

Review 4.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

Review 5.  SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.

Authors:  Mina K Chung; Sadashiva Karnik; Joshua Saef; Cornelia Bergmann; John Barnard; Michael M Lederman; John Tilton; Feixiong Cheng; Clifford V Harding; James B Young; Neil Mehta; Scott J Cameron; Keith R McCrae; Alvin H Schmaier; Jonathan D Smith; Ankur Kalra; Surafel K Gebreselassie; George Thomas; Edward S Hawkins; Lars G Svensson
Journal:  EBioMedicine       Date:  2020-08-06       Impact factor: 8.143

Review 6.  Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.

Authors:  Peng Zeng; Alvin Schmaier
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 6.208
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.